

REMARKS


The above amendments have been made to place the application in a more traditional format.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

5. (Amended) A composition comprising the compound as claimed in [any one of claims 1 to 4] claim 1 and a pharmaceutically acceptable carrier.

10. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in medicine.

11. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of Gram negative septic shock or another disease state involving elevated cytokine levels.

12. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of viral infection.

13. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of metastases or angiogenesis.